Cancer associated-fibroblast-derived exosomes in cancer progression

To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extrace...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 20; no. 1; pp. 154 - 19
Main Authors Li, Chao, Teixeira, Adilson Fonseca, Zhu, Hong-Jian, ten Dijke, Peter
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 01.12.2021
BioMed Central
BMC
Subjects
Adipocytes
Angiogenesis
Animals
B cells
Biomarkers
CAFs
Cancer
cancer cells
Cancer therapies
Cancer-Associated Fibroblasts - metabolism
Cell Communication
Cell growth
Cell interactions
Cell Transformation, Neoplastic - genetics
Cell Transformation, Neoplastic - metabolism
Chemoresistance
Chemotherapy
Cytokines
Development and progression
Disease Management
Disease Progression
Drug Development
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Endothelial cells
Energy Metabolism
Exosomes
Exosomes - metabolism
Extracellular matrix
Extracellular Matrix - metabolism
Extracellular vesicles
Extracellular Vesicles - metabolism
Fibroblasts
Health aspects
Humans
immune cells
Immune checkpoint inhibitors
Intercellular Junctions - metabolism
Lipids
Localization
Lymphocytes
Metabolism
Metastases
Metastasis
Models, Biological
Molecular Targeted Therapy
Morphology
Mutation
Neoplasms - drug therapy
Neoplasms - etiology
Neoplasms - metabolism
Neoplasms - pathology
Nucleic acids
Pancreatic cancer
Proteins
Review
TME
Tumor Microenvironment
Tumorigenesis
Vesicles
Wound healing
immune cells
cancer cells
CAFs
TME
biomarkers
exosomes
Online AccessGet full text

Cover

Abstract To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells and cancer associated fibroblasts (CAFs), which communicate with cancer cells and each other during tumor progression. CAFs are a dominant and heterogeneous cell type within the TME with a pivotal role in controlling cancer cell invasion and metastasis, immune evasion, angiogenesis and chemotherapy resistance. CAFs mediate their effects in part by remodeling the ECM and by secreting soluble factors and extracellular vesicles. Exosomes are a subtype of extracellular vesicles (EVs), which contain various biomolecules such as nucleic acids, lipids, and proteins. The biomolecules in exosomes can be transmitted from one to another cell, and thereby affect the behavior of the receiving cell. As exosomes are also present in circulation, their contents can also be explored as biomarkers for the diagnosis and prognosis of cancer patients. In this review, we concentrate on the role of CAFs-derived exosomes in the communication between CAFs and cancer cells and other cells of the TME. First, we introduce the multiple roles of CAFs in tumorigenesis. Thereafter, we discuss the ways CAFs communicate with cancer cells and interplay with other cells of the TME, and focus in particular on the role of exosomes. Then, we elaborate on the mechanisms by which CAFs-derived exosomes contribute to cancer progression, as well as and the clinical impact of exosomes. We conclude by discussing aspects of exosomes that deserve further investigation, including emerging insights into making treatment with immune checkpoint inhibitor blockade more efficient.
AbstractList To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells and cancer associated fibroblasts (CAFs), which communicate with cancer cells and each other during tumor progression. CAFs are a dominant and heterogeneous cell type within the TME with a pivotal role in controlling cancer cell invasion and metastasis, immune evasion, angiogenesis and chemotherapy resistance. CAFs mediate their effects in part by remodeling the ECM and by secreting soluble factors and extracellular vesicles. Exosomes are a subtype of extracellular vesicles (EVs), which contain various biomolecules such as nucleic acids, lipids, and proteins. The biomolecules in exosomes can be transmitted from one to another cell, and thereby affect the behavior of the receiving cell. As exosomes are also present in circulation, their contents can also be explored as biomarkers for the diagnosis and prognosis of cancer patients. In this review, we concentrate on the role of CAFs-derived exosomes in the communication between CAFs and cancer cells and other cells of the TME. First, we introduce the multiple roles of CAFs in tumorigenesis. Thereafter, we discuss the ways CAFs communicate with cancer cells and interplay with other cells of the TME, and focus in particular on the role of exosomes. Then, we elaborate on the mechanisms by which CAFs-derived exosomes contribute to cancer progression, as well as and the clinical impact of exosomes. We conclude by discussing aspects of exosomes that deserve further investigation, including emerging insights into making treatment with immune checkpoint inhibitor blockade more efficient. Keywords: TME, CAFs, cancer cells, immune cells, exosomes, biomarkers
To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells and cancer associated fibroblasts (CAFs), which communicate with cancer cells and each other during tumor progression. CAFs are a dominant and heterogeneous cell type within the TME with a pivotal role in controlling cancer cell invasion and metastasis, immune evasion, angiogenesis and chemotherapy resistance. CAFs mediate their effects in part by remodeling the ECM and by secreting soluble factors and extracellular vesicles. Exosomes are a subtype of extracellular vesicles (EVs), which contain various biomolecules such as nucleic acids, lipids, and proteins. The biomolecules in exosomes can be transmitted from one to another cell, and thereby affect the behavior of the receiving cell. As exosomes are also present in circulation, their contents can also be explored as biomarkers for the diagnosis and prognosis of cancer patients. In this review, we concentrate on the role of CAFs-derived exosomes in the communication between CAFs and cancer cells and other cells of the TME. First, we introduce the multiple roles of CAFs in tumorigenesis. Thereafter, we discuss the ways CAFs communicate with cancer cells and interplay with other cells of the TME, and focus in particular on the role of exosomes. Then, we elaborate on the mechanisms by which CAFs-derived exosomes contribute to cancer progression, as well as and the clinical impact of exosomes. We conclude by discussing aspects of exosomes that deserve further investigation, including emerging insights into making treatment with immune checkpoint inhibitor blockade more efficient.
To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells and cancer associated fibroblasts (CAFs), which communicate with cancer cells and each other during tumor progression. CAFs are a dominant and heterogeneous cell type within the TME with a pivotal role in controlling cancer cell invasion and metastasis, immune evasion, angiogenesis and chemotherapy resistance. CAFs mediate their effects in part by remodeling the ECM and by secreting soluble factors and extracellular vesicles. Exosomes are a subtype of extracellular vesicles (EVs), which contain various biomolecules such as nucleic acids, lipids, and proteins. The biomolecules in exosomes can be transmitted from one to another cell, and thereby affect the behavior of the receiving cell. As exosomes are also present in circulation, their contents can also be explored as biomarkers for the diagnosis and prognosis of cancer patients. In this review, we concentrate on the role of CAFs-derived exosomes in the communication between CAFs and cancer cells and other cells of the TME. First, we introduce the multiple roles of CAFs in tumorigenesis. Thereafter, we discuss the ways CAFs communicate with cancer cells and interplay with other cells of the TME, and focus in particular on the role of exosomes. Then, we elaborate on the mechanisms by which CAFs-derived exosomes contribute to cancer progression, as well as and the clinical impact of exosomes. We conclude by discussing aspects of exosomes that deserve further investigation, including emerging insights into making treatment with immune checkpoint inhibitor blockade more efficient.To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells and cancer associated fibroblasts (CAFs), which communicate with cancer cells and each other during tumor progression. CAFs are a dominant and heterogeneous cell type within the TME with a pivotal role in controlling cancer cell invasion and metastasis, immune evasion, angiogenesis and chemotherapy resistance. CAFs mediate their effects in part by remodeling the ECM and by secreting soluble factors and extracellular vesicles. Exosomes are a subtype of extracellular vesicles (EVs), which contain various biomolecules such as nucleic acids, lipids, and proteins. The biomolecules in exosomes can be transmitted from one to another cell, and thereby affect the behavior of the receiving cell. As exosomes are also present in circulation, their contents can also be explored as biomarkers for the diagnosis and prognosis of cancer patients. In this review, we concentrate on the role of CAFs-derived exosomes in the communication between CAFs and cancer cells and other cells of the TME. First, we introduce the multiple roles of CAFs in tumorigenesis. Thereafter, we discuss the ways CAFs communicate with cancer cells and interplay with other cells of the TME, and focus in particular on the role of exosomes. Then, we elaborate on the mechanisms by which CAFs-derived exosomes contribute to cancer progression, as well as and the clinical impact of exosomes. We conclude by discussing aspects of exosomes that deserve further investigation, including emerging insights into making treatment with immune checkpoint inhibitor blockade more efficient.
Abstract To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical successes achieved by targeting immune checkpoint inhibitors (ICIs). The TME consists of multiple cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells and cancer associated fibroblasts (CAFs), which communicate with cancer cells and each other during tumor progression. CAFs are a dominant and heterogeneous cell type within the TME with a pivotal role in controlling cancer cell invasion and metastasis, immune evasion, angiogenesis and chemotherapy resistance. CAFs mediate their effects in part by remodeling the ECM and by secreting soluble factors and extracellular vesicles. Exosomes are a subtype of extracellular vesicles (EVs), which contain various biomolecules such as nucleic acids, lipids, and proteins. The biomolecules in exosomes can be transmitted from one to another cell, and thereby affect the behavior of the receiving cell. As exosomes are also present in circulation, their contents can also be explored as biomarkers for the diagnosis and prognosis of cancer patients. In this review, we concentrate on the role of CAFs-derived exosomes in the communication between CAFs and cancer cells and other cells of the TME. First, we introduce the multiple roles of CAFs in tumorigenesis. Thereafter, we discuss the ways CAFs communicate with cancer cells and interplay with other cells of the TME, and focus in particular on the role of exosomes. Then, we elaborate on the mechanisms by which CAFs-derived exosomes contribute to cancer progression, as well as and the clinical impact of exosomes. We conclude by discussing aspects of exosomes that deserve further investigation, including emerging insights into making treatment with immune checkpoint inhibitor blockade more efficient.
ArticleNumber 154
Audience Academic
Author Li, Chao
Teixeira, Adilson Fonseca
Zhu, Hong-Jian
ten Dijke, Peter
Author_xml – sequence: 1
  givenname: Chao
  surname: Li
  fullname: Li, Chao
– sequence: 2
  givenname: Adilson Fonseca
  surname: Teixeira
  fullname: Teixeira, Adilson Fonseca
– sequence: 3
  givenname: Hong-Jian
  surname: Zhu
  fullname: Zhu, Hong-Jian
– sequence: 4
  givenname: Peter
  orcidid: 0000-0002-7234-342X
  surname: ten Dijke
  fullname: ten Dijke, Peter
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34852849$$D View this record in MEDLINE/PubMed
BookMark eNp9kkFv1DAUhC1URNuFP8ABrcSFS4rtOI59QapWtFSqxAXOluM8L14l9mJnK_bf87YppVshlIMj-5vxG2vOyUlMEQh5y-gFY0p-LIxrUVeUs4oyIetq_4KcMdHKSjRanTz5PyXnpWwoZa1qxStyWgvVcCX0GVmtbHSQl7aU5IKdoK986HLqBlumqocc7qBfwq9U0ghlGeLSzYJtTusMpYQUX5OX3g4F3jysC_L96vO31Zfq9uv1zerytnKS66mS3DpwwFSnetCWWw04g-yY06LtqbSOe5yKScskZThg5x2CTjYMbKdsvSA3s2-f7MZscxht3ptkg7nfSHltbJ6CG8A0utW-80q1rcSsUvWeOtr6GmStOnfw-jR7bXfdCL2DOGU7HJken8Tww6zTnVFoIPCxF-TDg0FOP3dQJjOG4mAYbIS0K4ZL2mAMLSmi75-hm7TLEZ8KKcbqhoua_aXWFgOE6BPe6w6m5lIqKepGMIHUxT8o_HoYg8N--ID7R4J3T4M-JvxTAQT4DLicSsngHxFGzaFnZu6ZwZ6Z-56ZPYrUM5ELk52wDDhOGP4n_Q2DpdbN
CitedBy_id crossref_primary_10_1002_jbt_70126
crossref_primary_10_1038_s41597_025_04410_4
crossref_primary_10_3389_fphar_2022_1011033
crossref_primary_10_3390_cancers15082307
crossref_primary_10_1007_s00259_025_07171_9
crossref_primary_10_1016_j_bbagen_2025_130796
crossref_primary_10_1186_s12903_023_03421_0
crossref_primary_10_1016_j_mocell_2024_100010
crossref_primary_10_1096_fj_202300203R
crossref_primary_10_1186_s12943_023_01761_7
crossref_primary_10_1111_cas_15726
crossref_primary_10_3390_cancers15072065
crossref_primary_10_1615_CritRevOncog_2022047088
crossref_primary_10_3389_fonc_2024_1349474
crossref_primary_10_3390_cancers14184526
crossref_primary_10_3389_fonc_2022_1022979
crossref_primary_10_1021_acsami_2c07143
crossref_primary_10_1016_j_cellsig_2023_110635
crossref_primary_10_1016_j_ijpharm_2024_124580
crossref_primary_10_3748_wjg_v29_i42_5699
crossref_primary_10_3389_fonc_2023_1191660
crossref_primary_10_3390_ijms252312548
crossref_primary_10_1016_j_celrep_2024_114721
crossref_primary_10_1007_s13205_024_04133_0
crossref_primary_10_1016_j_prp_2024_155766
crossref_primary_10_1002_jcp_31344
crossref_primary_10_1038_s41419_023_05965_z
crossref_primary_10_1038_s41392_023_01711_1
crossref_primary_10_1016_j_yexcr_2025_114508
crossref_primary_10_3389_fonc_2022_984560
crossref_primary_10_3390_cancers16244123
crossref_primary_10_1042_BST20221175
crossref_primary_10_1186_s12967_024_05238_z
crossref_primary_10_1186_s10020_023_00616_7
crossref_primary_10_1186_s13046_023_02926_4
crossref_primary_10_1007_s12015_023_10592_4
crossref_primary_10_1016_j_heliyon_2024_e28148
crossref_primary_10_1016_j_heliyon_2024_e31589
crossref_primary_10_1186_s12943_025_02279_w
crossref_primary_10_3390_biom14091099
crossref_primary_10_1002_jev2_70055
crossref_primary_10_1016_j_mbplus_2022_100111
crossref_primary_10_1007_s43032_024_01716_3
crossref_primary_10_1111_cas_16014
crossref_primary_10_1080_10408363_2024_2309935
crossref_primary_10_18632_aging_206088
crossref_primary_10_3389_fonc_2022_1052132
crossref_primary_10_3892_ol_2024_14300
crossref_primary_10_1038_s41598_022_26389_3
crossref_primary_10_1002_mco2_693
crossref_primary_10_3390_biomedicines11010112
crossref_primary_10_1186_s12885_024_12190_0
crossref_primary_10_1007_s13353_024_00830_x
crossref_primary_10_1016_j_bbrep_2024_101644
crossref_primary_10_1186_s12967_023_04473_0
crossref_primary_10_3390_ijms25021205
crossref_primary_10_1186_s12943_024_02165_x
crossref_primary_10_3389_fcell_2023_1089068
crossref_primary_10_1002_cam4_6408
crossref_primary_10_1039_D3TB03044J
crossref_primary_10_1186_s13550_024_01139_w
crossref_primary_10_1186_s12964_023_01408_6
crossref_primary_10_1186_s10020_023_00665_y
crossref_primary_10_3389_fimmu_2024_1409945
crossref_primary_10_3389_fphar_2024_1459938
crossref_primary_10_3390_cells13191666
crossref_primary_10_1016_j_drup_2023_100936
crossref_primary_10_1080_21655979_2022_2032972
crossref_primary_10_1016_j_drup_2023_100937
crossref_primary_10_1080_15384047_2024_2424490
crossref_primary_10_1186_s13045_024_01634_6
crossref_primary_10_3389_fimmu_2025_1548535
crossref_primary_10_1186_s12964_023_01136_x
crossref_primary_10_3389_fonc_2024_1368732
crossref_primary_10_1186_s40164_024_00564_w
crossref_primary_10_3389_fimmu_2022_975847
crossref_primary_10_3389_fphys_2023_1158839
crossref_primary_10_1016_j_tranon_2024_101924
crossref_primary_10_62347_VCCZ1477
crossref_primary_10_2147_IJN_S447350
crossref_primary_10_3389_fimmu_2024_1367373
crossref_primary_10_20517_cdr_2024_152
crossref_primary_10_3390_cancers15205103
crossref_primary_10_1016_j_gene_2025_149296
crossref_primary_10_1016_j_matbio_2024_06_004
crossref_primary_10_1007_s00432_024_06066_w
crossref_primary_10_1016_j_semcancer_2023_05_007
crossref_primary_10_2147_JIR_S493656
crossref_primary_10_1016_j_bbcan_2024_189137
crossref_primary_10_4049_jimmunol_2400335
crossref_primary_10_1007_s10528_023_10512_8
crossref_primary_10_3390_biomedicines11051326
crossref_primary_10_1016_j_phrs_2022_106475
crossref_primary_10_1186_s12943_024_02103_x
crossref_primary_10_3390_md21030151
crossref_primary_10_1080_15384047_2022_2072164
crossref_primary_10_1016_j_omto_2023_100752
crossref_primary_10_1016_j_intimp_2024_113133
crossref_primary_10_1111_cas_15801
crossref_primary_10_1097_MD_0000000000040082
crossref_primary_10_1360_TB_2023_0588
crossref_primary_10_1016_j_intimp_2024_112282
crossref_primary_10_1016_j_bbamcr_2024_119697
crossref_primary_10_25259_Cytojournal_149_2024
crossref_primary_10_1007_s00259_023_06146_y
crossref_primary_10_1007_s11010_023_04737_9
crossref_primary_10_3892_br_2024_1751
crossref_primary_10_1016_j_bbcan_2024_189189
crossref_primary_10_1016_j_cej_2022_139506
crossref_primary_10_3389_fimmu_2024_1431211
crossref_primary_10_1186_s12943_022_01670_1
crossref_primary_10_1016_j_cmet_2022_03_004
crossref_primary_10_3724_abbs_2023092
crossref_primary_10_1186_s12943_024_02106_8
crossref_primary_10_1007_s10495_022_01766_5
crossref_primary_10_1093_jmcb_mjae025
crossref_primary_10_1002_mco2_541
crossref_primary_10_1016_j_isci_2024_109350
crossref_primary_10_3390_biomedicines11092534
crossref_primary_10_1016_j_aohep_2024_101745
crossref_primary_10_1007_s13577_024_01056_z
crossref_primary_10_20517_cdr_2024_97
crossref_primary_10_1038_s41420_024_01958_9
crossref_primary_10_1186_s13062_024_00511_z
crossref_primary_10_1016_j_biopha_2023_114697
crossref_primary_10_1016_j_canlet_2022_215860
crossref_primary_10_1186_s12967_024_05266_9
crossref_primary_10_1080_08916934_2025_2458324
crossref_primary_10_3389_fgene_2022_1024508
crossref_primary_10_3389_fonc_2024_1480074
crossref_primary_10_3389_fonc_2022_846917
crossref_primary_10_1016_j_cca_2024_117875
crossref_primary_10_3389_fonc_2022_868726
crossref_primary_10_1002_mc_23668
crossref_primary_10_3389_fonc_2024_1382398
crossref_primary_10_1016_j_aca_2024_342819
crossref_primary_10_3389_fcell_2022_837585
crossref_primary_10_1186_s40364_025_00748_4
crossref_primary_10_3389_fonc_2023_1170893
crossref_primary_10_1186_s13045_023_01498_2
crossref_primary_10_1016_j_intimp_2022_109052
crossref_primary_10_1016_j_intimp_2023_110601
crossref_primary_10_1186_s12967_024_05854_9
crossref_primary_10_1177_11795972241274024
crossref_primary_10_1016_j_tranon_2023_101712
crossref_primary_10_2147_IJN_S413831
crossref_primary_10_1016_j_ccr_2023_215562
crossref_primary_10_1111_liv_15773
crossref_primary_10_1007_s12013_024_01496_2
crossref_primary_10_1080_17501911_2024_2430166
crossref_primary_10_1007_s10495_023_01819_3
crossref_primary_10_1016_j_phrs_2022_106418
crossref_primary_10_3389_fimmu_2022_802846
crossref_primary_10_1007_s12010_023_04782_6
crossref_primary_10_1186_s13048_024_01364_w
crossref_primary_10_1016_j_intimp_2023_110837
crossref_primary_10_1038_s41368_023_00274_9
crossref_primary_10_1016_j_jconrel_2023_03_013
crossref_primary_10_1186_s40164_024_00569_5
crossref_primary_10_1186_s12943_023_01860_5
crossref_primary_10_3390_cells13141166
crossref_primary_10_3390_ijms232315438
crossref_primary_10_1620_tjem_2024_J041
crossref_primary_10_1186_s12885_023_11028_5
crossref_primary_10_1016_j_envres_2023_116007
crossref_primary_10_1016_j_prp_2023_155002
crossref_primary_10_1016_j_ymthe_2022_12_005
crossref_primary_10_1038_s41598_022_20186_8
crossref_primary_10_1016_j_heliyon_2024_e29216
crossref_primary_10_1038_s41419_024_06494_z
crossref_primary_10_3389_fonc_2022_862723
crossref_primary_10_3390_ijms24087208
crossref_primary_10_1002_mog2_68
crossref_primary_10_1021_acs_jmedchem_5c00132
crossref_primary_10_1016_j_heliyon_2024_e27151
crossref_primary_10_62347_TIMD7591
crossref_primary_10_1016_j_cytogfr_2022_09_001
crossref_primary_10_1097_CJI_0000000000000539
crossref_primary_10_1186_s12943_024_02084_x
crossref_primary_10_1016_j_jdiacomp_2023_108435
crossref_primary_10_1080_10408347_2024_2339961
crossref_primary_10_1016_j_cellsig_2022_110567
crossref_primary_10_1021_acsnano_3c02272
Cites_doi 10.2174/1871520616666161031143301
10.7150/thno.22182
10.1038/s12276-020-00500-y
10.1038/s41568-019-0238-1
10.1007/978-1-4614-0899-4_2
10.1038/bjc.2013.768
10.1038/cr.2015.29
10.1056/NEJM198612253152606
10.1111/cas.14537
10.1080/15384047.2019.1685157
10.1182/blood.V79.3.650.650
10.1021/acs.jproteome.7b00925
10.1038/aps.2017.12
10.1016/j.ccr.2014.04.005
10.1038/s41575-019-0115-0
10.1186/s13045-017-0448-5
10.3390/cancers11050619
10.1016/j.canlet.2021.08.002
10.1002/jcp.27111
10.1038/s41467-018-07582-3
10.1053/j.gastro.2008.07.016
10.1038/s41571-020-0403-1
10.3389/fcell.2021.676319
10.1016/j.biomaterials.2017.01.004
10.3389/fimmu.2020.01612
10.1186/s12943-020-01168-8
10.1016/j.ccr.2014.05.004
10.1002/advs.202002518
10.1007/s00018-017-2595-9
10.1002/cam4.2873
10.1016/j.bbrc.2020.04.142
10.1186/s12967-020-02648-7
10.1016/j.trecan.2020.02.013
10.1159/000453133
10.1038/s41598-018-26411-7
10.1039/D0NR07622H
10.1074/mcp.M112.022806
10.1016/j.coph.2018.04.009
10.1016/j.cmet.2018.08.007
10.1158/1078-0432.CCR-18-0329
10.1186/s12943-019-0994-2
10.3389/fimmu.2018.00414
10.1038/mt.2014.202
10.1016/j.yexcr.2020.112113
10.1016/j.biopha.2020.110237
10.1038/s12276-020-0431-z
10.3748/wjg.v22.i30.6841
10.18632/oncotarget.21635
10.1016/j.ejmech.2017.11.056
10.3389/fonc.2019.00356
10.1002/pmic.201700456
10.1038/s41422-018-0060-4
10.1186/1471-2407-11-245
10.1038/s41577-020-0275-8
10.3390/cancers13030399
10.1002/cbf.1188
10.1016/j.cell.2017.01.018
10.1111/febs.14586
10.1038/s41420-021-00506-z
10.1002/ijc.29804
10.1038/ng.3818
10.1126/scisignal.aan8247
10.1073/pnas.1608384113
10.1038/s41419-018-1104-x
10.1186/s12885-021-08669-9
10.3389/fimmu.2020.01956
10.1038/nrm.2017.125
10.3389/fimmu.2019.01835
10.1186/s12943-017-0706-8
10.3390/cancers12010056
10.1172/JCI80011
10.1016/j.tranon.2021.101047
10.1126/scisignal.2003084
10.4049/jimmunol.160.10.5053
10.1016/j.pharmthera.2018.02.013
10.1007/s00018-019-03351-7
10.1007/s00281-018-0689-6
10.1055/s-0039-1687908
10.1155/2021/8839978
10.1038/ncb3021
10.1111/cas.14346
10.1080/09553002.2019.1589653
10.1126/science.aau6977
10.1038/s41586-018-0392-8
10.1158/2159-8290.CD-19-1384
10.1002/ijc.32193
10.1007/978-3-319-74470-4_7
10.1038/nature07869
10.3390/cells8040307
10.1242/dmm.029447
10.3389/fimmu.2020.02026
10.1186/s12943-019-0973-7
10.1158/2159-8290.CD-18-0193
10.3390/ijms21165840
10.1016/j.tips.2014.09.006
10.7554/eLife.10250
10.1002/path.4034
10.1073/pnas.1203479109
10.1016/j.biomaterials.2021.120964
10.1146/annurev.bi.60.070191.001433
10.1186/s12943-018-0758-4
10.7150/thno.26546
10.3390/cancers11050689
10.1242/dev.128.16.3117
10.1016/j.omtn.2020.11.003
10.1016/j.trecan.2020.03.007
10.1159/000495232
10.7150/thno.25541
10.1016/j.canlet.2016.01.043
10.4161/cc.8.23.10238
10.1053/j.seminoncol.2017.10.004
10.1038/s41388-019-0765-y
10.3892/or.2014.3047
10.1084/jem.20162024
10.3390/ijms21072576
10.1093/brain/awaa110
10.1074/jbc.M114.588046
10.1016/j.coi.2020.03.004
10.1073/pnas.022324499
10.1152/physrev.00048.2019
10.1016/j.cell.2020.03.013
10.1016/j.ebiom.2018.09.006
10.1002/anie.201506262
10.1038/onc.2015.315
10.1016/j.cmet.2018.09.012
10.3233/CBM-160575
10.1002/cam4.993
10.1002/ijc.25612
10.1016/j.trecan.2019.09.009
10.1016/j.cell.2019.05.012
10.1007/s004030050180
10.1038/s41573-018-0004-1
10.1186/s12943-019-0991-5
10.1038/s41467-019-11718-4
10.1016/j.trecan.2020.03.002
10.1016/j.canlet.2011.12.020
10.1007/s10571-016-0366-z
10.3727/096504018X15336368805108
10.1016/j.ccell.2018.01.011
10.1186/s13046-019-1144-9
10.3390/ijms20040840
10.1111/imr.12657
10.1016/j.canlet.2019.10.039
10.1038/ncb2000
10.1016/j.yjmcc.2016.03.005
10.1016/j.omtn.2019.11.024
10.3390/cancers12040857
10.1038/nrgastro.2012.115
10.1080/20013078.2020.1785161
10.1007/s13402-020-00500-0
10.7150/thno.53412
10.1016/j.ceb.2018.09.002
10.1007/s12010-020-03244-7
10.1038/onc.2013.191
10.3390/cancers12051232
10.1158/0008-5472.CAN-19-0454
10.1016/j.ymthe.2016.10.009
10.3390/ijms21155373
10.18632/oncotarget.14752
10.1242/dmm.036236
10.1002/anie.201912524
10.1158/2159-8290.CD-19-0644
10.1158/1541-7786.MCR-18-0891
10.1016/j.cell.2011.02.013
10.1158/2159-8290.CD-19-0094
10.1158/1078-0432.CCR-15-2851
10.1007/978-3-319-78127-3_6
10.1038/nature19084
10.1016/j.prp.2019.152729
10.1186/s12935-019-1051-3
10.1038/ncomms16031
10.1016/j.cell.2020.07.009
10.1016/j.devcel.2019.04.011
10.1016/j.celrep.2019.01.009
10.1038/s41568-019-0235-4
10.1136/jitc-2020-001698
10.1080/20013078.2018.1535750
10.1111/cas.13735
10.3389/fimmu.2019.01394
10.1084/jem.20140692
10.3390/ijms18061153
10.1016/j.ygyno.2015.04.015
10.1080/14789450.2020.1713103
10.7150/ijbs.10666
10.1093/qjmed/hcz093
10.2217/imt-2016-0135
10.1016/j.trecan.2016.05.010
10.1016/j.yjmcc.2016.01.011
10.1038/s41392-020-00261-0
10.1002/pmic.201700167
10.1146/annurev-biochem-013118-111902
10.1007/s10456-019-09688-8
10.1016/j.canlet.2017.03.004
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-021-01463-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
CrossRef
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 19
ExternalDocumentID oai_doaj_org_article_5979fbf8877648568df0c07f3e638bca
PMC8638446
A686435414
34852849
10_1186_s12943_021_01463_y
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: CGC.NL
  grantid: CGC.NL
– fundername: ;
– fundername: ;
  grantid: CGC.NL
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c629t-62acece18b8de9a2a9e2846b1c947d06ac2f52816a1601852bfcde9c651eab8a3
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:18:14 EDT 2025
Thu Aug 21 13:52:49 EDT 2025
Fri Jul 11 10:44:25 EDT 2025
Fri Jul 25 06:49:40 EDT 2025
Tue Jun 17 21:28:29 EDT 2025
Tue Jun 10 20:45:31 EDT 2025
Thu Apr 03 06:53:37 EDT 2025
Thu Apr 24 22:51:55 EDT 2025
Tue Jul 01 01:01:19 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords immune cells
cancer cells
CAFs
TME
biomarkers
exosomes
Language English
License 2021. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c629t-62acece18b8de9a2a9e2846b1c947d06ac2f52816a1601852bfcde9c651eab8a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-7234-342X
OpenAccessLink https://www.proquest.com/docview/2611352431?pq-origsite=%requestingapplication%
PMID 34852849
PQID 2611352431
PQPubID 42702
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_5979fbf8877648568df0c07f3e638bca
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8638446
proquest_miscellaneous_2605601960
proquest_journals_2611352431
gale_infotracmisc_A686435414
gale_infotracacademiconefile_A686435414
pubmed_primary_34852849
crossref_primary_10_1186_s12943_021_01463_y
crossref_citationtrail_10_1186_s12943_021_01463_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-01
PublicationDateYYYYMMDD 2021-12-01
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References SA Simpkins (1463_CR83) 2012; 227
MC Knox (1463_CR30) 2020; 11
M Shimoda (1463_CR132) 2014; 16
YY Li (1463_CR151) 2018; 36
D Unterleuthner (1463_CR69) 2020; 23
DB Wright (1463_CR96) 2014; 35
Y Ren (1463_CR62) 2018; 17
Y Song (1463_CR12) 2020; 11
T Ji (1463_CR49) 2016; 55
M Ligorio (1463_CR60) 2019; 178
1463_CR196
W Li (1463_CR126) 2017; 16
I Valiente-Alandi (1463_CR97) 2016; 91
A Datta (1463_CR183) 2018; 8
NP Hessvik (1463_CR114) 2018; 75
A Kaur (1463_CR101) 2019; 9
M Paauwe (1463_CR64) 2018; 24
Y Qu (1463_CR91) 2002; 99
LR Languino (1463_CR195) 2016; 8
G Zhao (1463_CR145) 2020; 9
E Lee (1463_CR159) 2016; 18
N McGranahan (1463_CR175) 2017; 168
1463_CR10
AJ Groot (1463_CR161) 2012; 727
Y Gao (1463_CR134) 2020; 7
Y Mizutani (1463_CR39) 2019; 79
1463_CR13
1463_CR15
Y Kieffer (1463_CR46) 2020; 10
HR Herschman (1463_CR2) 1991; 60
HP Ehrlich (1463_CR38) 2006; 24
T Bertero (1463_CR103) 2019; 29
HM Brechbuhl (1463_CR53) 2017; 23
1463_CR177
S Pavlides (1463_CR79) 2009; 8
I Wortzel (1463_CR169) 2019; 49
D Hanahan (1463_CR1) 2011; 144
E Sahai (1463_CR35) 2020; 20
K Popowski (1463_CR197) 2020; 9
1463_CR28
P Yu (1463_CR181) 2012; 109
H Li (1463_CR44) 2017; 49
ER Abels (1463_CR120) 2016; 36
JJ Lin (1463_CR164) 2016; 2
Y Li (1463_CR130) 2020; 191
LP Sun (1463_CR152) 2019; 42
M Erkan (1463_CR18) 2012; 9
G van Niel (1463_CR124) 2018; 19
X Wang (1463_CR148) 2019; 38
M Demory Beckler (1463_CR194) 2013; 12
M Simian (1463_CR98) 2001; 128
M Ostrowski (1463_CR119) 2010; 12
W Nie (1463_CR189) 2020; 59
G Biffi (1463_CR22) 2021; 101
J Wang (1463_CR179) 2021; 14
AM van der Leun (1463_CR170) 2020; 20
VS LeBleu (1463_CR26) 2020; 6
Z Zhang (1463_CR149) 2017; 397
D Dou (1463_CR174) 2020; 11
N Kubo (1463_CR67) 2016; 22
LL Cheng (1463_CR190) 2021; 275
J Dai (1463_CR111) 2020; 5
S Ayala-Mar (1463_CR184) 2021; 2021
M Nurmik (1463_CR25) 2020; 146
W Li (1463_CR157) 2017; 8
DM Pegtel (1463_CR125) 2019; 88
C Gu (1463_CR140) 2020; 527
T Yong (1463_CR187) 2019; 10
P Vaupel (1463_CR78) 2019; 95
S Principe (1463_CR154) 2018; 17
XJ Shen (1463_CR82) 2015; 11
O Olivares (1463_CR84) 2017; 8
E Koh (1463_CR188) 2017; 121
T Tian (1463_CR122) 2014; 289
X Zhao (1463_CR191) 2020; 128
L Monteran (1463_CR102) 2019; 10
L Wilde (1463_CR81) 2017; 44
PI Ribeiro Franco (1463_CR6) 2020; 216
JE Kim (1463_CR136) 2020; 469
N Nishida-Aoki (1463_CR182) 2017; 25
H Zhao (1463_CR162) 2016; 5
X Luan (1463_CR185) 2017; 38
BL Li (1463_CR142) 2019; 234
1463_CR8
JW Wang (1463_CR155) 2019; 27
BC Ozdemir (1463_CR52) 2014; 25
D Ohlund (1463_CR17) 2014; 211
AE Denton (1463_CR9) 2018; 1060
T Li (1463_CR76) 2012; 318
K Fanhchaksai (1463_CR54) 2016; 138
R Kanzaki (1463_CR19) 2020; 111
1463_CR109
MW Graner (1463_CR33) 2018; 40
M Curtis (1463_CR85) 2019; 29
J You (1463_CR150) 2019; 112
S Staubach (1463_CR117) 2018; 18
M Bartoschek (1463_CR47) 2018; 9
1463_CR108
JL Reading (1463_CR171) 2018; 283
A Zhang (1463_CR73) 2017; 6
N Nouraee (1463_CR144) 2016; 16
X Yang (1463_CR110) 2019; 9
IV Pinchuk (1463_CR75) 2008; 135
1463_CR113
D von Ahrens (1463_CR127) 2017; 10
G Shan (1463_CR128) 2021; 44
L Duan (1463_CR186) 2021; 13
L Mashouri (1463_CR115) 2019; 18
CM Sousa (1463_CR105) 2016; 536
S Adachi (1463_CR94) 1992; 79
Q Zhang (1463_CR176) 2019; 27
J Ren (1463_CR137) 2018; 8
A Trautmann (1463_CR95) 1998; 160
Z Yu (1463_CR118) 2020; 143
E Flaberg (1463_CR50) 2011; 128
B Roucourt (1463_CR116) 2015; 25
X Chen (1463_CR139) 2021; 24
SJ Engle (1463_CR51) 1999; 59
G Comito (1463_CR74) 2014; 33
H Wang (1463_CR129) 2020; 19
JN Mills (1463_CR166) 2018; 41
G Chen (1463_CR173) 2018; 560
D Ohlund (1463_CR41) 2017; 214
Y Yang (1463_CR180) 2018; 28
L Ziani (1463_CR16) 2018; 9
MP Bebelman (1463_CR112) 2018; 188
A Gonda (1463_CR121) 2019; 17
A Santi (1463_CR99) 2018; 18
H Zhang (1463_CR146) 2020; 19
X Bian (1463_CR107) 2019; 18
HF Dvorak (1463_CR3) 2019; 45
N Seo (1463_CR29) 2018; 109
L Schwartz (1463_CR77) 2017; 17
L Zhou (1463_CR138) 2021; 19
HF Dvorak (1463_CR4) 1986; 315
L Wei (1463_CR57) 2018; 9
AJ Petty (1463_CR71) 2017; 9
K Yang (1463_CR141) 2021; 21
X Chen (1463_CR55) 2019; 18
T Wu (1463_CR7) 2017; 387
1463_CR72
H Shi (1463_CR147) 2021; 9
GM Sundaram (1463_CR5) 2018; 285
Y Zhan (1463_CR135) 2021; 7
1463_CR143
A Trautmann (1463_CR93) 1997; 289
SF Ahmed (1463_CR192) 2015; 23
Y Huang (1463_CR32) 2018; 1056
S Kale (1463_CR61) 2015; 34
G Shan (1463_CR158) 2020; 52
ME Fiori (1463_CR37) 2019; 18
X Qin (1463_CR58) 2018; 8
WS Lee (1463_CR14) 2020; 52
U Putz (1463_CR193) 2012; 5
D Park (1463_CR40) 2020; 181
B Chandra Jena (1463_CR21) 2021; 520
R Lugano (1463_CR66) 2020; 77
1463_CR86
1463_CR153
W Yan (1463_CR31) 2020; 6
1463_CR87
1463_CR89
J Barbazan (1463_CR56) 2019; 56
A Miyasaka (1463_CR160) 2015; 138
1463_CR80
H Kobayashi (1463_CR24) 2019; 16
HO Lee (1463_CR100) 2011; 11
SM Morrissey (1463_CR178) 2020; 6
AI Shagufta (1463_CR165) 2018; 143
1463_CR123
R Barrett (1463_CR36) 2020; 64
T Valencia (1463_CR104) 2014; 26
B Chen (1463_CR133) 2021; 11
Q Sun (1463_CR70) 2018; 8
HX Tan (1463_CR65) 2020; 21
M Luo (1463_CR92) 2018; 51
CX Dominguez (1463_CR48) 2020; 10
C Thery (1463_CR106) 2018; 7
L Chen (1463_CR172) 2015; 125
Y Miyai (1463_CR20) 2020; 111
E Donnarumma (1463_CR131) 2017; 8
J Pellman (1463_CR88) 2016; 94
R Derynck (1463_CR34) 2020; 18
L Bu (1463_CR23) 2019; 38
E Elyada (1463_CR42) 2019; 9
S Maeda (1463_CR90) 2009; 458
G Wang (1463_CR168) 2014; 31
P Sharma (1463_CR11) 2020; 20
A Hoshino (1463_CR27) 2020; 182
Y Yu (1463_CR63) 2014; 110
G Landskron (1463_CR59) 2019; 10
MP Lux (1463_CR167) 2016; 11
A Costa (1463_CR43) 2018; 33
H Guo (1463_CR156) 2019; 19
K Hosaka (1463_CR45) 2016; 113
1463_CR68
DI Cantor (1463_CR163) 2020; 17
References_xml – volume: 17
  start-page: 164
  issue: 2
  year: 2017
  ident: 1463_CR77
  publication-title: Anti Cancer Agents Med Chem
  doi: 10.2174/1871520616666161031143301
– volume: 8
  start-page: 921
  issue: 4
  year: 2018
  ident: 1463_CR58
  publication-title: Theranostics.
  doi: 10.7150/thno.22182
– volume: 52
  start-page: 1475
  issue: 9
  year: 2020
  ident: 1463_CR14
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-020-00500-y
– volume: 20
  start-page: 174
  issue: 3
  year: 2020
  ident: 1463_CR35
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0238-1
– volume: 18
  start-page: 553
  issue: 9
  year: 2016
  ident: 1463_CR159
  publication-title: Which Promotes Prostate Cancer Metastasis Neoplasia
– volume: 727
  start-page: 15
  year: 2012
  ident: 1463_CR161
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4614-0899-4_2
– volume: 110
  start-page: 724
  issue: 3
  year: 2014
  ident: 1463_CR63
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.768
– volume: 25
  start-page: 412
  issue: 4
  year: 2015
  ident: 1463_CR116
  publication-title: Cell Res
  doi: 10.1038/cr.2015.29
– volume: 315
  start-page: 1650
  issue: 26
  year: 1986
  ident: 1463_CR4
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198612253152606
– volume: 111
  start-page: 2708
  issue: 8
  year: 2020
  ident: 1463_CR19
  publication-title: Cancer Sci
  doi: 10.1111/cas.14537
– volume: 21
  start-page: 258
  issue: 3
  year: 2020
  ident: 1463_CR65
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2019.1685157
– volume: 79
  start-page: 650
  issue: 3
  year: 1992
  ident: 1463_CR94
  publication-title: Blood.
  doi: 10.1182/blood.V79.3.650.650
– volume: 17
  start-page: 2045
  issue: 6
  year: 2018
  ident: 1463_CR154
  publication-title: J Proteome Res
  doi: 10.1021/acs.jproteome.7b00925
– volume: 38
  start-page: 754
  issue: 6
  year: 2017
  ident: 1463_CR185
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/aps.2017.12
– volume: 25
  start-page: 719
  issue: 6
  year: 2014
  ident: 1463_CR52
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2014.04.005
– volume: 16
  start-page: 282
  issue: 5
  year: 2019
  ident: 1463_CR24
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-019-0115-0
– volume: 10
  start-page: 76
  issue: 1
  year: 2017
  ident: 1463_CR127
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0448-5
– ident: 1463_CR86
  doi: 10.3390/cancers11050619
– volume: 520
  start-page: 222
  year: 2021
  ident: 1463_CR21
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2021.08.002
– volume: 234
  start-page: 2943
  issue: 3
  year: 2019
  ident: 1463_CR142
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27111
– volume: 9
  start-page: 5150
  issue: 1
  year: 2018
  ident: 1463_CR47
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-07582-3
– volume: 135
  start-page: 1228
  issue: 4
  year: 2008
  ident: 1463_CR75
  publication-title: Gastroenterology.
  doi: 10.1053/j.gastro.2008.07.016
– volume: 18
  start-page: 9
  issue: 1
  year: 2020
  ident: 1463_CR34
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-020-0403-1
– volume: 9
  year: 2021
  ident: 1463_CR147
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2021.676319
– volume: 121
  start-page: 121
  year: 2017
  ident: 1463_CR188
  publication-title: Biomaterials.
  doi: 10.1016/j.biomaterials.2017.01.004
– volume: 11
  start-page: 1612
  year: 2020
  ident: 1463_CR30
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.01612
– volume: 19
  start-page: 43
  issue: 1
  year: 2020
  ident: 1463_CR146
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01168-8
– volume: 26
  start-page: 121
  issue: 1
  year: 2014
  ident: 1463_CR104
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2014.05.004
– volume: 7
  start-page: 2002518
  issue: 21
  year: 2020
  ident: 1463_CR134
  publication-title: Adv Sci (Weinh)
  doi: 10.1002/advs.202002518
– volume: 75
  start-page: 193
  issue: 2
  year: 2018
  ident: 1463_CR114
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-017-2595-9
– volume: 9
  start-page: 2500
  issue: 7
  year: 2020
  ident: 1463_CR145
  publication-title: Cancer Med
  doi: 10.1002/cam4.2873
– volume: 527
  start-page: 638
  issue: 3
  year: 2020
  ident: 1463_CR140
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2020.04.142
– volume: 19
  start-page: 8
  issue: 1
  year: 2021
  ident: 1463_CR138
  publication-title: J Transl Med
  doi: 10.1186/s12967-020-02648-7
– volume: 6
  start-page: 506
  issue: 6
  year: 2020
  ident: 1463_CR31
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2020.02.013
– volume: 11
  start-page: 398
  issue: 6
  year: 2016
  ident: 1463_CR167
  publication-title: Breast Care (Basel)
  doi: 10.1159/000453133
– volume: 8
  start-page: 8161
  issue: 1
  year: 2018
  ident: 1463_CR183
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-26411-7
– volume: 13
  start-page: 1387
  issue: 3
  year: 2021
  ident: 1463_CR186
  publication-title: Nanoscale.
  doi: 10.1039/D0NR07622H
– volume: 12
  start-page: 343
  issue: 2
  year: 2013
  ident: 1463_CR194
  publication-title: Mol Cell Proteomics
  doi: 10.1074/mcp.M112.022806
– volume: 41
  start-page: 59
  year: 2018
  ident: 1463_CR166
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2018.04.009
– volume: 29
  start-page: 141
  issue: 1
  year: 2019
  ident: 1463_CR85
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.08.007
– volume: 24
  start-page: 6331
  issue: 24
  year: 2018
  ident: 1463_CR64
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0329
– volume: 18
  start-page: 70
  issue: 1
  year: 2019
  ident: 1463_CR37
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-0994-2
– volume: 9
  start-page: 414
  year: 2018
  ident: 1463_CR16
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.00414
– volume: 23
  start-page: 255
  issue: 2
  year: 2015
  ident: 1463_CR192
  publication-title: Mol Ther
  doi: 10.1038/mt.2014.202
– ident: 1463_CR143
  doi: 10.1016/j.yexcr.2020.112113
– volume: 128
  year: 2020
  ident: 1463_CR191
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2020.110237
– volume: 52
  start-page: 1809
  issue: 11
  year: 2020
  ident: 1463_CR158
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-020-0431-z
– volume: 22
  start-page: 6841
  issue: 30
  year: 2016
  ident: 1463_CR67
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v22.i30.6841
– volume: 8
  start-page: 96035
  issue: 56
  year: 2017
  ident: 1463_CR157
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.21635
– volume: 143
  start-page: 515
  year: 2018
  ident: 1463_CR165
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2017.11.056
– volume: 9
  start-page: 356
  year: 2019
  ident: 1463_CR110
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.00356
– volume: 18
  issue: 7
  year: 2018
  ident: 1463_CR117
  publication-title: Proteomics.
  doi: 10.1002/pmic.201700456
– volume: 28
  start-page: 862
  issue: 8
  year: 2018
  ident: 1463_CR180
  publication-title: Cell Res
  doi: 10.1038/s41422-018-0060-4
– volume: 11
  start-page: 245
  year: 2011
  ident: 1463_CR100
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-11-245
– volume: 20
  start-page: 75
  issue: 2
  year: 2020
  ident: 1463_CR11
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-0275-8
– ident: 1463_CR80
  doi: 10.3390/cancers13030399
– volume: 24
  start-page: 63
  issue: 1
  year: 2006
  ident: 1463_CR38
  publication-title: Cell Biochem Funct
  doi: 10.1002/cbf.1188
– volume: 168
  start-page: 613
  issue: 4
  year: 2017
  ident: 1463_CR175
  publication-title: Cell.
  doi: 10.1016/j.cell.2017.01.018
– volume: 285
  start-page: 4516
  issue: 24
  year: 2018
  ident: 1463_CR5
  publication-title: FEBS J
  doi: 10.1111/febs.14586
– volume: 7
  start-page: 141
  issue: 1
  year: 2021
  ident: 1463_CR135
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-021-00506-z
– volume: 138
  start-page: 630
  issue: 3
  year: 2016
  ident: 1463_CR54
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29804
– volume: 49
  start-page: 708
  issue: 5
  year: 2017
  ident: 1463_CR44
  publication-title: Nat Genet
  doi: 10.1038/ng.3818
– ident: 1463_CR68
  doi: 10.1126/scisignal.aan8247
– volume: 113
  start-page: E5618
  issue: 38
  year: 2016
  ident: 1463_CR45
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1608384113
– volume: 9
  start-page: 1065
  issue: 11
  year: 2018
  ident: 1463_CR57
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-018-1104-x
– volume: 21
  start-page: 933
  issue: 1
  year: 2021
  ident: 1463_CR141
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08669-9
– volume: 11
  start-page: 1956
  year: 2020
  ident: 1463_CR12
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.01956
– volume: 19
  start-page: 213
  issue: 4
  year: 2018
  ident: 1463_CR124
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm.2017.125
– volume: 10
  start-page: 1835
  year: 2019
  ident: 1463_CR102
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.01835
– volume: 16
  start-page: 145
  issue: 1
  year: 2017
  ident: 1463_CR126
  publication-title: Mol Cancer
  doi: 10.1186/s12943-017-0706-8
– ident: 1463_CR153
  doi: 10.3390/cancers12010056
– volume: 125
  start-page: 3384
  issue: 9
  year: 2015
  ident: 1463_CR172
  publication-title: J Clin Invest
  doi: 10.1172/JCI80011
– volume: 14
  issue: 5
  year: 2021
  ident: 1463_CR179
  publication-title: Transl Oncol
  doi: 10.1016/j.tranon.2021.101047
– volume: 5
  start-page: ra70
  issue: 243
  year: 2012
  ident: 1463_CR193
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2003084
– volume: 160
  start-page: 5053
  issue: 10
  year: 1998
  ident: 1463_CR95
  publication-title: J Immunol
  doi: 10.4049/jimmunol.160.10.5053
– volume: 188
  start-page: 1
  year: 2018
  ident: 1463_CR112
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2018.02.013
– volume: 77
  start-page: 1745
  issue: 9
  year: 2020
  ident: 1463_CR66
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-019-03351-7
– volume: 40
  start-page: 505
  issue: 5
  year: 2018
  ident: 1463_CR33
  publication-title: Semin Immunopathol
  doi: 10.1007/s00281-018-0689-6
– volume: 45
  start-page: 576
  issue: 6
  year: 2019
  ident: 1463_CR3
  publication-title: Semin Thromb Hemost
  doi: 10.1055/s-0039-1687908
– volume: 2021
  start-page: 8839978
  year: 2021
  ident: 1463_CR184
  publication-title: J Immunol Res
  doi: 10.1155/2021/8839978
– volume: 16
  start-page: 889
  issue: 9
  year: 2014
  ident: 1463_CR132
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3021
– volume: 111
  start-page: 1047
  issue: 4
  year: 2020
  ident: 1463_CR20
  publication-title: Cancer Sci
  doi: 10.1111/cas.14346
– volume: 95
  start-page: 912
  issue: 7
  year: 2019
  ident: 1463_CR78
  publication-title: Int J Radiat Biol
  doi: 10.1080/09553002.2019.1589653
– ident: 1463_CR113
  doi: 10.1126/science.aau6977
– volume: 560
  start-page: 382
  issue: 7718
  year: 2018
  ident: 1463_CR173
  publication-title: Nature.
  doi: 10.1038/s41586-018-0392-8
– volume: 10
  start-page: 1330
  issue: 9
  year: 2020
  ident: 1463_CR46
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-1384
– volume: 59
  start-page: 3379
  issue: 14
  year: 1999
  ident: 1463_CR51
  publication-title: Cancer Res
– volume: 146
  start-page: 895
  issue: 4
  year: 2020
  ident: 1463_CR25
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32193
– volume: 1056
  start-page: 109
  year: 2018
  ident: 1463_CR32
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-3-319-74470-4_7
– volume: 458
  start-page: 597
  issue: 7238
  year: 2009
  ident: 1463_CR90
  publication-title: Nature.
  doi: 10.1038/nature07869
– ident: 1463_CR28
  doi: 10.3390/cells8040307
– ident: 1463_CR15
  doi: 10.1242/dmm.029447
– volume: 11
  start-page: 2026
  year: 2020
  ident: 1463_CR174
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.02026
– volume: 18
  start-page: 50
  issue: 1
  year: 2019
  ident: 1463_CR107
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-0973-7
– volume: 9
  start-page: 64
  issue: 1
  year: 2019
  ident: 1463_CR101
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0193
– ident: 1463_CR13
  doi: 10.3390/ijms21165840
– volume: 35
  start-page: 567
  issue: 11
  year: 2014
  ident: 1463_CR96
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2014.09.006
– volume: 5
  year: 2016
  ident: 1463_CR162
  publication-title: Elife.
  doi: 10.7554/eLife.10250
– volume: 227
  start-page: 490
  issue: 4
  year: 2012
  ident: 1463_CR83
  publication-title: J Pathol
  doi: 10.1002/path.4034
– volume: 109
  start-page: 6187
  issue: 16
  year: 2012
  ident: 1463_CR181
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1203479109
– volume: 275
  year: 2021
  ident: 1463_CR190
  publication-title: Biomaterials.
  doi: 10.1016/j.biomaterials.2021.120964
– volume: 60
  start-page: 281
  year: 1991
  ident: 1463_CR2
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.bi.60.070191.001433
– volume: 17
  start-page: 5
  issue: 1
  year: 2018
  ident: 1463_CR62
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0758-4
– volume: 8
  start-page: 5072
  issue: 18
  year: 2018
  ident: 1463_CR70
  publication-title: Theranostics.
  doi: 10.7150/thno.26546
– ident: 1463_CR72
  doi: 10.3390/cancers11050689
– volume: 128
  start-page: 3117
  issue: 16
  year: 2001
  ident: 1463_CR98
  publication-title: Development.
  doi: 10.1242/dev.128.16.3117
– volume: 24
  start-page: 113
  year: 2021
  ident: 1463_CR139
  publication-title: Mol Ther Nucleic Acids.
  doi: 10.1016/j.omtn.2020.11.003
– volume: 6
  start-page: 767
  issue: 9
  year: 2020
  ident: 1463_CR26
  publication-title: Trends Cancer.
  doi: 10.1016/j.trecan.2020.03.007
– volume: 51
  start-page: 315
  issue: 1
  year: 2018
  ident: 1463_CR92
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000495232
– volume: 8
  start-page: 3932
  issue: 14
  year: 2018
  ident: 1463_CR137
  publication-title: Theranostics.
  doi: 10.7150/thno.25541
– volume: 387
  start-page: 61
  year: 2017
  ident: 1463_CR7
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.01.043
– volume: 8
  start-page: 3984
  issue: 23
  year: 2009
  ident: 1463_CR79
  publication-title: Cell Cycle
  doi: 10.4161/cc.8.23.10238
– volume: 44
  start-page: 198
  issue: 3
  year: 2017
  ident: 1463_CR81
  publication-title: Semin Oncol
  doi: 10.1053/j.seminoncol.2017.10.004
– volume: 38
  start-page: 4887
  issue: 25
  year: 2019
  ident: 1463_CR23
  publication-title: Oncogene.
  doi: 10.1038/s41388-019-0765-y
– volume: 31
  start-page: 1839
  issue: 4
  year: 2014
  ident: 1463_CR168
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3047
– volume: 214
  start-page: 579
  issue: 3
  year: 2017
  ident: 1463_CR41
  publication-title: J Exp Med
  doi: 10.1084/jem.20162024
– ident: 1463_CR123
  doi: 10.3390/ijms21072576
– volume: 143
  start-page: 1780
  issue: 6
  year: 2020
  ident: 1463_CR118
  publication-title: Brain.
  doi: 10.1093/brain/awaa110
– volume: 289
  start-page: 22258
  issue: 32
  year: 2014
  ident: 1463_CR122
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.588046
– volume: 64
  start-page: 80
  year: 2020
  ident: 1463_CR36
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2020.03.004
– volume: 99
  start-page: 697
  issue: 2
  year: 2002
  ident: 1463_CR91
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.022324499
– volume: 101
  start-page: 147
  issue: 1
  year: 2021
  ident: 1463_CR22
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00048.2019
– volume: 181
  start-page: 486
  issue: 2
  year: 2020
  ident: 1463_CR40
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.03.013
– volume: 36
  start-page: 209
  year: 2018
  ident: 1463_CR151
  publication-title: EBioMedicine.
  doi: 10.1016/j.ebiom.2018.09.006
– volume: 55
  start-page: 1050
  issue: 3
  year: 2016
  ident: 1463_CR49
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201506262
– volume: 34
  start-page: 5408
  issue: 42
  year: 2015
  ident: 1463_CR61
  publication-title: Oncogene.
  doi: 10.1038/onc.2015.315
– volume: 29
  start-page: 124
  issue: 1
  year: 2019
  ident: 1463_CR103
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.09.012
– volume: 16
  start-page: 367
  issue: 3
  year: 2016
  ident: 1463_CR144
  publication-title: Cancer Biomark
  doi: 10.3233/CBM-160575
– volume: 6
  start-page: 463
  issue: 2
  year: 2017
  ident: 1463_CR73
  publication-title: Cancer Med.
  doi: 10.1002/cam4.993
– volume: 128
  start-page: 2793
  issue: 12
  year: 2011
  ident: 1463_CR50
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25612
– ident: 1463_CR196
  doi: 10.1016/j.trecan.2019.09.009
– volume: 178
  start-page: 160
  issue: 1
  year: 2019
  ident: 1463_CR60
  publication-title: Cell.
  doi: 10.1016/j.cell.2019.05.012
– volume: 289
  start-page: 194
  issue: 4
  year: 1997
  ident: 1463_CR93
  publication-title: Arch Dermatol Res
  doi: 10.1007/s004030050180
– volume: 18
  start-page: 99
  issue: 2
  year: 2019
  ident: 1463_CR55
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-018-0004-1
– volume: 18
  start-page: 75
  issue: 1
  year: 2019
  ident: 1463_CR115
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-0991-5
– volume: 10
  start-page: 3838
  issue: 1
  year: 2019
  ident: 1463_CR187
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-11718-4
– volume: 6
  start-page: 550
  issue: 7
  year: 2020
  ident: 1463_CR178
  publication-title: Trends Cancer.
  doi: 10.1016/j.trecan.2020.03.002
– volume: 318
  start-page: 154
  issue: 2
  year: 2012
  ident: 1463_CR76
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2011.12.020
– volume: 36
  start-page: 301
  issue: 3
  year: 2016
  ident: 1463_CR120
  publication-title: Cell Mol Neurobiol
  doi: 10.1007/s10571-016-0366-z
– volume: 27
  start-page: 979
  issue: 9
  year: 2019
  ident: 1463_CR155
  publication-title: Oncol Res
  doi: 10.3727/096504018X15336368805108
– volume: 33
  start-page: 463
  issue: 3
  year: 2018
  ident: 1463_CR43
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.01.011
– volume: 38
  start-page: 151
  issue: 1
  year: 2019
  ident: 1463_CR148
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-019-1144-9
– ident: 1463_CR8
  doi: 10.3390/ijms20040840
– volume: 283
  start-page: 194
  issue: 1
  year: 2018
  ident: 1463_CR171
  publication-title: Immunol Rev
  doi: 10.1111/imr.12657
– volume: 469
  start-page: 256
  year: 2020
  ident: 1463_CR136
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.10.039
– volume: 12
  start-page: 19
  issue: 1
  year: 2010
  ident: 1463_CR119
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2000
– volume: 94
  start-page: 22
  year: 2016
  ident: 1463_CR88
  publication-title: J Mol Cell Cardiol
  doi: 10.1016/j.yjmcc.2016.03.005
– volume: 19
  start-page: 654
  year: 2020
  ident: 1463_CR129
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2019.11.024
– ident: 1463_CR89
  doi: 10.3390/cancers12040857
– volume: 9
  start-page: 454
  issue: 8
  year: 2012
  ident: 1463_CR18
  publication-title: Nat Rev Gastroenterol Hepatol.
  doi: 10.1038/nrgastro.2012.115
– volume: 9
  start-page: 1785161
  issue: 1
  year: 2020
  ident: 1463_CR197
  publication-title: J Extracell Vesicles
  doi: 10.1080/20013078.2020.1785161
– volume: 44
  start-page: 45
  issue: 1
  year: 2021
  ident: 1463_CR128
  publication-title: Cell Oncol (Dordr)
  doi: 10.1007/s13402-020-00500-0
– volume: 11
  start-page: 3932
  issue: 8
  year: 2021
  ident: 1463_CR133
  publication-title: Theranostics.
  doi: 10.7150/thno.53412
– volume: 56
  start-page: 71
  year: 2019
  ident: 1463_CR56
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/j.ceb.2018.09.002
– volume: 191
  start-page: 1084
  issue: 3
  year: 2020
  ident: 1463_CR130
  publication-title: Appl Biochem Biotechnol
  doi: 10.1007/s12010-020-03244-7
– volume: 33
  start-page: 2423
  issue: 19
  year: 2014
  ident: 1463_CR74
  publication-title: Oncogene.
  doi: 10.1038/onc.2013.191
– ident: 1463_CR87
  doi: 10.3390/cancers12051232
– volume: 79
  start-page: 5367
  issue: 20
  year: 2019
  ident: 1463_CR39
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-0454
– volume: 25
  start-page: 181
  issue: 1
  year: 2017
  ident: 1463_CR182
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2016.10.009
– ident: 1463_CR109
  doi: 10.3390/ijms21155373
– volume: 42
  start-page: 1319
  issue: 4
  year: 2019
  ident: 1463_CR152
  publication-title: Oncol Rep
– volume: 8
  start-page: 19592
  issue: 12
  year: 2017
  ident: 1463_CR131
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.14752
– ident: 1463_CR10
  doi: 10.1242/dmm.036236
– volume: 59
  start-page: 2018
  issue: 5
  year: 2020
  ident: 1463_CR189
  publication-title: Angew Chem Int Ed Engl.
  doi: 10.1002/anie.201912524
– volume: 10
  start-page: 232
  issue: 2
  year: 2020
  ident: 1463_CR48
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-19-0644
– volume: 17
  start-page: 337
  issue: 2
  year: 2019
  ident: 1463_CR121
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-18-0891
– volume: 144
  start-page: 646
  issue: 5
  year: 2011
  ident: 1463_CR1
  publication-title: Cell.
  doi: 10.1016/j.cell.2011.02.013
– volume: 9
  start-page: 1102
  issue: 8
  year: 2019
  ident: 1463_CR42
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-19-0094
– volume: 23
  start-page: 1710
  issue: 7
  year: 2017
  ident: 1463_CR53
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2851
– volume: 1060
  start-page: 99
  year: 2018
  ident: 1463_CR9
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-3-319-78127-3_6
– volume: 536
  start-page: 479
  issue: 7617
  year: 2016
  ident: 1463_CR105
  publication-title: Nature.
  doi: 10.1038/nature19084
– volume: 216
  issue: 1
  year: 2020
  ident: 1463_CR6
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2019.152729
– volume: 19
  start-page: 347
  year: 2019
  ident: 1463_CR156
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-019-1051-3
– volume: 8
  start-page: 16031
  year: 2017
  ident: 1463_CR84
  publication-title: Nat Commun
  doi: 10.1038/ncomms16031
– volume: 182
  start-page: 1044
  issue: 4
  year: 2020
  ident: 1463_CR27
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.07.009
– volume: 49
  start-page: 347
  issue: 3
  year: 2019
  ident: 1463_CR169
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2019.04.011
– volume: 27
  start-page: 940
  issue: 3
  year: 2019
  ident: 1463_CR176
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2019.01.009
– volume: 20
  start-page: 218
  issue: 4
  year: 2020
  ident: 1463_CR170
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0235-4
– ident: 1463_CR177
  doi: 10.1136/jitc-2020-001698
– volume: 7
  start-page: 1535750
  issue: 1
  year: 2018
  ident: 1463_CR106
  publication-title: J Extracell Vesicles.
  doi: 10.1080/20013078.2018.1535750
– volume: 109
  start-page: 2998
  issue: 10
  year: 2018
  ident: 1463_CR29
  publication-title: Cancer Sci
  doi: 10.1111/cas.13735
– volume: 10
  start-page: 1394
  year: 2019
  ident: 1463_CR59
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.01394
– volume: 211
  start-page: 1503
  issue: 8
  year: 2014
  ident: 1463_CR17
  publication-title: J Exp Med
  doi: 10.1084/jem.20140692
– ident: 1463_CR108
  doi: 10.3390/ijms18061153
– volume: 138
  start-page: 174
  issue: 1
  year: 2015
  ident: 1463_CR160
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2015.04.015
– volume: 17
  start-page: 49
  issue: 1
  year: 2020
  ident: 1463_CR163
  publication-title: Expert Rev Proteomics
  doi: 10.1080/14789450.2020.1713103
– volume: 11
  start-page: 370
  issue: 4
  year: 2015
  ident: 1463_CR82
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.10666
– volume: 112
  start-page: 581
  issue: 8
  year: 2019
  ident: 1463_CR150
  publication-title: QJM.
  doi: 10.1093/qjmed/hcz093
– volume: 9
  start-page: 289
  issue: 3
  year: 2017
  ident: 1463_CR71
  publication-title: Immunotherapy.
  doi: 10.2217/imt-2016-0135
– volume: 2
  start-page: 350
  issue: 7
  year: 2016
  ident: 1463_CR164
  publication-title: Trends Cancer.
  doi: 10.1016/j.trecan.2016.05.010
– volume: 91
  start-page: 228
  year: 2016
  ident: 1463_CR97
  publication-title: J Mol Cell Cardiol
  doi: 10.1016/j.yjmcc.2016.01.011
– volume: 5
  start-page: 145
  issue: 1
  year: 2020
  ident: 1463_CR111
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-00261-0
– volume: 18
  issue: 5–6
  year: 2018
  ident: 1463_CR99
  publication-title: Proteomics.
  doi: 10.1002/pmic.201700167
– volume: 88
  start-page: 487
  year: 2019
  ident: 1463_CR125
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev-biochem-013118-111902
– volume: 8
  start-page: 2432
  issue: 5
  year: 2016
  ident: 1463_CR195
  publication-title: Am J Transl Res
– volume: 23
  start-page: 159
  issue: 2
  year: 2020
  ident: 1463_CR69
  publication-title: Angiogenesis.
  doi: 10.1007/s10456-019-09688-8
– volume: 397
  start-page: 33
  year: 2017
  ident: 1463_CR149
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.03.004
SSID ssj0017874
Score 2.6724741
SecondaryResourceType review_article
Snippet To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of clinical...
Abstract To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of attention in recent years in particular with the advent of...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 154
SubjectTerms Adipocytes
Angiogenesis
Animals
B cells
Biomarkers
CAFs
Cancer
cancer cells
Cancer therapies
Cancer-Associated Fibroblasts - metabolism
Cell Communication
Cell growth
Cell interactions
Cell Transformation, Neoplastic - genetics
Cell Transformation, Neoplastic - metabolism
Chemoresistance
Chemotherapy
Cytokines
Development and progression
Disease Management
Disease Progression
Drug Development
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Endothelial cells
Energy Metabolism
Exosomes
Exosomes - metabolism
Extracellular matrix
Extracellular Matrix - metabolism
Extracellular vesicles
Extracellular Vesicles - metabolism
Fibroblasts
Health aspects
Humans
immune cells
Immune checkpoint inhibitors
Intercellular Junctions - metabolism
Lipids
Localization
Lymphocytes
Metabolism
Metastases
Metastasis
Models, Biological
Molecular Targeted Therapy
Morphology
Mutation
Neoplasms - drug therapy
Neoplasms - etiology
Neoplasms - metabolism
Neoplasms - pathology
Nucleic acids
Pancreatic cancer
Proteins
Review
TME
Tumor Microenvironment
Tumorigenesis
Vesicles
Wound healing
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KIKWXkqYvp2lxodBDMbFlaSwdk6UhFNJTA7kJPWmgtUt2U7L_PiPLu6wptJderRFIo28886HRDMAHq5SQoeFES6ypuAiysl50VYNeGVm7zrH0GvnyK15c8S_X4nqn1VfKCcvlgbPiTijgVdFGsoUOuRQofaxd3cU2EHKsG0Mj8nkbMjXdHxAM-eaJjMSTJXk1nu4rE3Xm2FbrmRsaq_X_-U_ecUrzhMkdD3R-AE-n0LE8zUt-Bo9Cfwj7uZnk-hAeX07X5M9hsUhneVuaSffBV5Fo8WApVF5VnkD3O_gy3A_L4WdYljd96fKEMVsrV-p4AVfnn78tLqqpW0LlkKlVhcy44EIjrfRBGWZUINeDtnGKd75G41gUTDZoGiJhUjAbHQk6FE0wVpr2Jez1Qx9eQ-kZdp5jraIjduZqJTGK0CIqVmOMooBmozztplLiqaPFDz1SCok6K1yTwvWocL0u4NN2zq9cSOOv0mfpTLaSqQj2-IGgoSdo6H9Bo4CP6UR1MlVanjPTiwPaZCp6pU9RUjyW-qAXcDyTJBNz8-ENJvRk4ktN1LOh6JUCsALeb4fTzJS21ofhLsnUifESSyzgVYbQdkstLZkOSBXQzcA12_N8pL_5PhYAl7Q_ovFH_0NJb-AJS3YxZugcw97q9i68pThrZd-NJvUA6XsjnQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA9aUXwRrV-rVVYQfJDQTW6TTZ6kHpYi1CcL9xbyqQXdrbfX0vvvndnNrV2Evm4mkGQ-f5vJDCHvndZCRVYDLHGW1iIq6oJoKJNBW1X5xnN8jXz6TZ6c1V9XYpV_uPU5rXJnEwdDHTqP_8gPIdJnECyAv_t08Ydi1yi8Xc0tNO6Se1i6DFO6mtUEuBgIY717KKPkYQ--rcZbSwTQtVzQ7cwZDTX7_7fMN1zTPG3yhh86fkwe5QCyPBo5_oTcie0-uT-2lNzukwen-bL8KVkukaPr0mYOxEATgOPOQcC8oQFE7yqGMl53ffc79uV5W_pxwpCzNdbreEbOjr98X57Q3DOBesn1hkpuffSRKadC1JZbHcEBSce8rptQSet5ElwxaRlAMSW4Sx4IvRQsWqfs4jnZa7s2viRl4LIJtax08oDRfKWVTCIupNS8kimJgrDd4RmfC4pjX4tfZgAWSprxwA0cuBkO3GwL8nGaczGW07iV-jPyZKLEUtjDh279w2TNMoCIdHIJjGUjayWkCqnyVZMWEUyL87YgH5CjBhUWludtfncAm8TSV-ZIKojKsBt6QQ5mlKBofj68kwmTFb03_8SyIO-mYZyJyWtt7C6RpkLcC1ixIC9GEZq2tIAlA4N0QZqZcM32PB9pz38OZcAV7A_A_Kvbl_WaPOQo8UMGzgHZ26wv4xuIozbu7aAsfwE2cRsA
  priority: 102
  providerName: ProQuest
Title Cancer associated-fibroblast-derived exosomes in cancer progression
URI https://www.ncbi.nlm.nih.gov/pubmed/34852849
https://www.proquest.com/docview/2611352431
https://www.proquest.com/docview/2605601960
https://pubmed.ncbi.nlm.nih.gov/PMC8638446
https://doaj.org/article/5979fbf8877648568df0c07f3e638bca
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED_tQyBeEIyvwKiChMQDCiRpcrYfEOqqTVOlTgio1DfLduwxaSTQdmj97zk7aVnEhHiqFJ9T-z5894vtO4DXWoiS26wgWKJVUpSWJ7oqWZJhJRRPDTO5v408PcPTWTGZl_Md2JQ76hi4vBXa-XpSs8Xlu-uf649k8B-CwXN8vySfVfjdSA-MCxwm613YJ8_EvKFOiz-7CqScYZe5YEjDEnxziebWd_QcVcjn__eqfcNt9Y9U3vBRJw_gfhdcxqNWGx7Cjq0P4E5bbnJ9AHen3Ub6IxiPvbQXseqkY6vEEXBuNAXTq6Qitfxlq9heN8vmu13GF3Vs2g7hPFeby-MxzE6Ov45Pk66eQmIwF6sEc2WssRnXvLJC5UpYck6oMyMKVqWoTO7KnGeoMoJpvMy1M0RosMys0lwNn8Be3dT2GcRVjqwqMBXOEH4zqeDoSjtEFHmKzpURZBvmSdMlG_c1Ly5lAB0cZctwSQyXgeFyHcHbbZ8fbaqNf1IfeZlsKX2a7PCgWZzLzuokoSXhtKOFlGHBS-SVS03K3NDSsqONiuCNl6j06kXDM6q7k0CT9Gmx5Ag5RWy-UnoEhz1KMkLTb97ohNzosCRwmlF8SyFaBK-2zb6nP9hW2-bK06QeExOOjOBpq0LbKQ1pyCQgEQHrKVdvzv2W-uJbSBHOaX4E9J__x_--gHu5V_twROcQ9laLK_uSAq2VHsAum7MB7I9Gky8T-j06Pvv0eRA-WwyCZf0G79IncQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrXhcEJRXoECQQBxQ1MRxHPuAULu02tLuCqFW6s34FagESdndAvun-I2M86IRUm-9rscre95fbM8AvNRCZNwlFGGJVhHNHI-0zfIoYVYoHpvcEP8aeTpjk2P64SQ7WYM_3VsYf62y84m1o7aV8d_ItzDTTzBZwHj37uxH5LtG-dPVroVGoxYHbvULIdvi7f57lO8rQvZ2j8aTqO0qEBlGxDJiRBlnXMI1t04oooRDF810YgTNbcyUIUVGeMJUgmCFZ0QXBgkNyxKnNFcp_u81WKcpjo5gfWd39vFTf26B6k-7pzmcbS0wmlJ_TuohO2VptBqEv7pLwP-x4EIwHF7UvBD59u7A7TZlDbcbHbsLa67cgOtNE8vVBtyYtsfz92A89jo0D1Urc2ejAuF4pTFFX0YWlf2ns6H7XS2q724RnpahaSbUt8SaCiH34fhK-PkARmVVukcQWsJyS1ksCoOo0MSCsyJzKWOCxKwosgCSjnnStCXMfSeNb7KGMpzJhuESGS5rhstVAG_6OWdNAY9LqXe8THpKX3y7_qGaf5GtLUvEYKLQBbrnnFGeMW6L2MR5kTp0ZtqoAF57iUrvInB5RrUvHXCTvtiW3GYc80Dffz2AzQElmrYZDnc6IVvXspD_DCGAF_2wn-mvy5WuOvc0sUfaiE4DeNioUL-lFJeMAhIB5APlGux5OFKefq0Lj3PcH6Xs8eXLeg43J0fTQ3m4Pzt4AreI1_76_s8mjJbzc_cUs7ilftaaTgifr9pa_wK4wlqD
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+associated-fibroblast-derived+exosomes+in+cancer+progression&rft.jtitle=Molecular+cancer&rft.au=Li%2C+Chao&rft.au=Teixeira%2C+Adilson+Fonseca&rft.au=Zhu%2C+Hong-Jian&rft.au=Ten+Dijke%2C+Peter&rft.date=2021-12-01&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=20&rft.issue=1&rft.spage=154&rft_id=info:doi/10.1186%2Fs12943-021-01463-y&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon